Warner Chilcott plc, a prominent player in the pharmaceutical industry, is headquartered in Ireland (IE) and operates extensively across North America and Europe. Founded in 2000, the company has established itself as a leader in the development and marketing of branded prescription pharmaceuticals, particularly in women's health, dermatology, and urology. With a focus on innovative products, Warner Chilcott offers a range of unique medications that address specific health needs, setting them apart in a competitive market. The company has achieved significant milestones, including strategic acquisitions that have expanded its product portfolio and market reach. Recognised for its commitment to quality and patient care, Warner Chilcott continues to strengthen its position as a trusted name in the pharmaceutical sector.
How does Warner Chilcott plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Warner Chilcott plc's score of 41 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Warner Chilcott plc, headquartered in Ireland (IE), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of AbbVie Inc., which influences its climate commitments and reporting practices. As part of its corporate family, Warner Chilcott's climate initiatives and targets are cascaded from AbbVie Inc. This includes adherence to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are managed at the level of AbbVie Inc. While specific reduction targets for Warner Chilcott are not detailed, the overarching commitments from AbbVie Inc. suggest a focus on sustainability and emissions reduction. The company is expected to align with industry standards and best practices in climate action, although no explicit climate pledges or reduction targets have been documented for Warner Chilcott itself. In summary, while Warner Chilcott plc does not provide specific emissions data or reduction targets, it is positioned within a corporate structure that prioritises climate commitments through its parent company, AbbVie Inc.
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2010 | 2011 | 2012 | 2015 | 2016 | 2017 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 28,218,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 59,189,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Warner Chilcott plc has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.